Lck-IN-5 (example C10) is a potent and selective lymphocyte-specific protein tyrosine kinase ( LCK ) inhibitor. Lck-IN-5 selectively disrupts the interaction between the SH3 domain of LCK and the RK motif of CD3ε, thereby impairing LCK recruitment to the TCR. Lck-IN-5 modulates the activity of CD3ε-containing CAR and TRuC T cells, attenuating cytokine production and promoting a central-memory-like phenotype associated with enhanced persistence. Lck-IN-5 can be used for autoimmune diseases and graft-versus-host disease research [1].
References:
[1]. Nadine M. Woessner, et al. Controlling TCR and CAR activation by targeting LCK recruitment with a first-in-class small-molecule inhibitor. bioRxiv. December 12, 2025.
References:
[1]. Nadine M. Woessner, et al. Controlling TCR and CAR activation by targeting LCK recruitment with a first-in-class small-molecule inhibitor. bioRxiv. December 12, 2025.